Alchemy deep-dives

Investigator’s Brochure

What is an Investigator’s Brochure?

An Investigator’s Brochure (IB) is a compilation of the clinical and nonclinical information on an investigational medicinal product (IMP) that is relevant to its study in human participants. Its purpose, as set out in International Council for Harmonisation (ICH) E6(R3) Appendix A [1], is to give investigators and other trial personnel the information they need to understand the rationale for the clinical trial and to comply with key features of the protocol, such as the dose, dosing interval, method of administration, and safety monitoring procedures.

Rather than being an exhaustive repository of everything known about a product, the IB is a focused, investigator-facing document. It should present a concise, objective account of the IMP’s known and potential risks and benefits, so that investigators can conduct the trial safely and in a scientifically sound manner, and so that trial participants are properly protected.

When is an IB required, and when should it be updated?

Sponsors are generally responsible for ensuring that an up-to-date IB is developed and maintained for their clinical development programme, in accordance with applicable regulatory requirements. Practically, the need to prepare an original IB typically arises alongside a Sponsor’s decision to begin clinical development of a new IMP, to progress to a first-in-human (FIH) trial, or to prepare a Clinical Trial Application (CTA) or Investigational New Drug (IND) application.

Where an authorised product is being studied for a new indication or use, an indication- or use‑specific IB is generally expected unless there is a documented rationale for relying on a single IB across indications. Where permitted by the applicable regulatory framework, current product information, such as a Summary of Product Characteristics (SmPC) or equivalent basic product information, may be used in place of a full IB for authorised products. Whether this alternative is available, and on what basis, depends on the jurisdiction and the specific regulatory pathway, so this should always be confirmed against the applicable requirements rather than assumed.

 

Review, revision and communication of new information

The IB should be reviewed at least annually. Annual review, however, is a review obligation, not an automatic trigger for a new version. A review may conclude that no substantive revision is needed. Separately, the IB should be revised whenever important new information emerges that could affect the risk-benefit assessment, the safety of trial participants, or the conduct of the trial, and important safety information should be communicated to investigators promptly, even where formal revision of the IB itself takes longer.

Examples of information that may trigger an IB update, following appropriate Sponsor assessment, include:

  • A change to the Reference Safety Information (RSI)
  • A new safety signal
  • A newly reported serious adverse reaction
  • A new nonclinical toxicology finding
  • Important new clinical efficacy data
  • A significant change to the risk-benefit assessment
  • A change to dosage recommendations
  • A change to monitoring or risk-mitigation measures

These are illustrative triggers rather than an exhaustive or automatic list. Whether any particular piece of new information warrants an IB revision depends on a documented Sponsor assessment of its materiality.

Where an IB is revised, the current version should be provided to investigators, and, where required by the applicable regulatory framework, submitted or notified to the relevant regulatory authority and/or provided to the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) in accordance with local amendment procedures. Not every jurisdiction treats an updated IB as automatically requiring a fresh regulatory submission; the applicable notification, amendment, or submission requirements should be confirmed on a country-by-country basis.

What information does an IB contain?

The content and level of detail of an IB should reflect the stage of development and the nature of the IMP and should evolve as new relevant information becomes available. ICH E6(R3) Appendix A sets out a broad structure for the IB [1], generally comprising a summary, an introduction, information on the IMP’s physical, chemical and pharmaceutical properties and formulation, a summary of nonclinical studies, and a summary of effects in humans, concluding with a summary of data and guidance for the investigator.

As applicable to the stage of development and nature of the product, the IB should provide a concise, objective account of relevant pharmacology, pharmacokinetics (PK) and pharmacodynamics, toxicology, clinical safety and efficacy data, dose and administration information, and relevant pharmaceutical or manufacturing characteristics. Nonclinical findings should be presented in the context of their relevance to the proposed human use, and clinical data should support investigators’ understanding of the IMP’s safety and potential benefits. Where applicable, the IB should include the RSI and a risk-benefit assessment based on the available evidence.

Compared with ICH E6(R2) [2], E6(R3) is deliberately less prescriptive about the precise structure and placement of IB content. Sponsors therefore have some flexibility in how information is organised, provided the IB remains clear, logically structured, and accessible to investigators, and provided it contains all information relevant to the safe and scientifically sound conduct of the trial. It is not the case that every category of information listed in guidance is required in every IB; the appropriate content depends on the specific IMP, indication and stage of development.

What are the key regulatory requirements for an IB?

IB requirements combine internationally harmonised Good Clinical Practice (GCP) principles with jurisdiction-specific rules. A globally focused writing agency needs to work across all of these, rather than defaulting to any single jurisdiction’s framework.

ICH E6(R3) – international harmonised guidance

ICH E6(R3) [1], the current version of the ICH Guideline for GCP, sets out harmonised expectations for the IB in Appendix A. As a harmonised guideline rather than binding law in most regions, its application is generally given effect through national or regional legislation and regulatory guidance. Several jurisdictions, including the United Kingdom (UK), have recently strengthened the legal status of ICH GCP within their domestic frameworks (see below).

United States Food and Drug Administration (FDA) requirements

Under 21 Code of Federal Regulations (CFR) 312.23(a)(5) [3] and 21 CFR 312.55 [4], Sponsors submitting an IND are generally required to provide investigators with an IB containing specified information, and to keep investigators informed, as the investigation proceeds, of new observations relevant to the IMP’s safety and use. The IB is an important mechanism for meeting this ongoing obligation to keep investigators informed, but it is not necessarily the only permissible mechanism. Sponsors may also communicate important new safety information through other means, such as safety letters, pending formal revision of the IB. These FDA requirements apply to INDs regulated by the FDA and should not be read as a universal international standard.

European Union (EU) requirements

In the EU, Regulation (EU) No 536/2014 (the Clinical Trials Regulation [CTR]) sets out requirements relevant to the IB as part of the clinical trial application and conduct framework [5]. The CTR is an EU‑specific legal instrument, distinct from ICH guidance, and its requirements apply to clinical trials falling within its scope conducted in EU/European Economic Area member states.

UK requirements

UK clinical trials are governed by the Medicines for Human Use (Clinical Trials) Regulations 2004 [6], as amended by the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 [7]. The amended regulations took full effect on 28 April 2026 and apply to clinical trials of IMPs across all four UK nations.

Among other changes, the amended regulations require clinical trials of IMPs to be conducted in accordance with the principles of GCP set out in the ICH Guideline for Good Clinical Practice. Medicines and Healthcare products Regulatory Agency (MHRA) guidance explains how ICH E6(R3) is implemented and enforced in the UK, including the extent to which the guideline applies to trials intended to support a marketing authorisation application and to other trials. Sponsors and writing teams working on UK trials should refer to current MHRA and Health Research Authority (HRA) guidance, including the transitional arrangements guidance, rather than relying on the pre‑2026 framework.

How are Investigator’s Brochures used?

The IB serves several audiences. Investigators and site staff use it to understand the rationale for the trial, the properties of the IMP, and the procedures needed to manage participants safely. IRBs/IECs and equivalent ethics bodies use the IB, alongside the protocol and informed consent materials, to assess the proposed risk-benefit profile, dose, route of administration and safety monitoring procedures, and to judge whether investigators have the information they need to conduct the trial safely.

The RSI within the IB identifies the adverse reactions considered expected for the IMP, based on the Sponsor’s causality and severity assessment. Its principal regulatory role is to support the assessment of expectedness for individual case safety reports, in particular the identification of suspected unexpected serious adverse reactions (SUSARs) that require expedited reporting to regulatory authorities. It is not simply a list of adverse events observed with the IMP; it is a defined, Sponsor-maintained reference against which reported reactions are compared.

The IB’s risk-benefit assessment should give a concise, objective account of the IMP’s known and potential risks and the anticipated benefits of its use, supported by the available evidence, together with relevant risk-mitigation measures. This is intended to allow investigators and clinicians to form their own judgement of the risk-benefit profile of the IMP and the trial, and to support the clinical management of participants.

Appropriate medical and scientific oversight during IB development helps ensure that input from the different contributing functions is interpreted accurately and presented in a form that is useful to investigators and clinicians. This is best practice supported by the collaborative, cross‑functional nature of IB development, rather than a specific regulatory mandate that a physician personally draft or approve every IB. Sponsors should apply oversight arrangements appropriate to their organisation and the complexity of the programme.

What source materials and input are needed to write an IB?

Because the IB draws together information from across a development programme, producing a high‑quality IB typically requires input from multiple sources. Some of the material below feeds directly into the IB’s content; other items are source documents or data that inform the IB without being reproduced in full. The relevant sources will depend on the stage of development and data available, and some content may be provided as functional input rather than as a discrete source document.

Core IB sources

  1. Previous IB versions (for updates, or for a new indication-specific IB)
  2. Nonclinical data sources such as nonclinical study reports (e.g. receptor binding, in vitro and animal studies) and nonclinical written summaries
  3. Clinical Study Reports (CSRs) and clinical summaries – CSRs, Integrated Summary of Safety and Integrated Summary of Efficacy
  4. Clinical trial safety databases, for example where data are needed to support an IB update ahead of final CSRs
  5. Pharmacovigilance and safety surveillance outputs – Development Safety Update Reports, SUSAR analyses, the current RSI, risk‑benefit assessments, safety signal evaluations and aggregate safety assessments
  6. Clinical pharmacology sources – clinical pharmacology study reports, integrated and population PK summaries, and exposure-response reports
  7. CMC and quality information – the Investigational Medicinal Product Dossier (IMPD, used in the EU/UK), the IND CMC section, CMC regulatory submissions, and drug product/substance specifications and stability data
  8. Published literature, particularly relevant for established compounds or repurposed products
  9. Post-marketing data, where the product is marketed in any jurisdiction – spontaneous adverse event reports, global safety databases, periodic safety reports and regulatory safety communications
  10. Product labelling and prescribing information, where marketed (e.g. US Prescribing Information, SmPCs and package inserts)
  11. Clinical study protocols for the programme
  12. Regulatory documents and correspondence – IND/CTA submission documents, FDA briefing documents, and correspondence, advice and meeting minutes with agencies such as the European Medicines Agency, MHRA or FDA (e.g. Type B meetings such as end-of-phase 2 meetings)

How long does it take to write an IB?

IBs are substantial, cross-functional documents, and timelines vary considerably depending on the circumstances. Relevant factors include whether the IB is a new document or an update, the stage of development, the volume and maturity of the available data, the number of functional contributors involved, the Sponsor’s review and approval processes, and, where applicable, any linked regulatory submission timelines.

As general, indicative guidance only: an annual update with a modest volume of new data may be achievable within a few weeks, while a new IB supporting a FIH programme is more often measured in months, not least because the clinical development team is typically working on the IB alongside the wider CTA/IND package at the same time. Early alignment on scope and structure, prompt provision of source materials, and timely first-draft input from all functional contributors all help keep an IB programme on track, but no specific timeline can be guaranteed for any individual programme.

Overview of the development of an IB

 

How Alchemy can help

Alchemy’s medical writers support IBs at every stage, from FIH documents through routine annual updates.

IB content coordination: Our writers draw on their regulatory writing experience to guide the IB through drafting and review, coordinating input and recommendations from the range of functions typically involved – clinical, clinical pharmacology, nonclinical (including toxicology), pharmacovigilance, regulatory affairs, CMC and biostatistics.

Document publishing: We prepare the IB for submission-ready publishing, including PDF output suitable for regulatory and IRB/IEC submission.

IB updates: When a change to the RSI, a new safety signal, a nonclinical or clinical finding, or a change to dosage or risk-mitigation measures prompts an update, our team works with the study team to revise the IB efficiently, tracking the knock-on effects across its interlinked sections.

Associated documents: We also support a wide range of related programme and submission documents, and would be glad to discuss your broader writing support needs.

To discuss your IB needs, please contact our team at alchemymedicalwriting.com/contact.

Top tip for authoring IBs by Senior Medical Writer, Dr Euan Paterson

My top tip for authoring IBs is to bring the different source elements together as early as possible in the drafting process and seek functional input at the earliest opportunity. IBs draw on a wide range of data sources and require input from multiple members of the development team, each bringing valuable functional expertise. Our Alchemy writers work closely with our clients’ functional experts to identify the content needed from each function, guide them on the level of detail required, and then tailor and integrate their input to meet the regulatory requirements and intended audience of the IB.

References

  1. ICH E6(R3) Guideline for Good Clinical Practice, Appendix A: Investigator’s Brochure. Available at: https://ichgcp.net/appendix-a-ich-e6-r3
  2. ICH E6(R2) Guideline for Good Clinical Practice. Available at: ICH: E6(R2): Guideline for good clinical practice – Step 5
  3. 21 Code of Federal Regulations 312.23(a)(5). Available at: eCFR: 21 CFR 312.23 – IND content and format
  4. 21 Code of Federal Regulations 312.55. Available at: eCFR: 21 CFR 312.55 – Informing investigators
  5. Regulation (EU) No 536/2014. Available at: Clinical trials – Regulation EU No 536/2014 – Public Health
  6. Medicines for Human Use (Clinical Trials) Regulations 2004. Available at: The Medicines for Human Use (Clinical Trials) Regulations 2004
  7. Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025. Available at: The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025

Ready to experience medical writing excellence?

Trust us to create clear, concise, and expertly edited documents that meet your objectives and help to evolve tomorrow’s treatment landscape.

Get in Touch